title: Diagnostic Performance of HPV E6/E7 mRNA and HPV DNA Assays for the Detection and Screening of Oncogenic Human Papillomavirus Infection among Woman with Cervical Lesions in China.
abstract: BACKGROUND
  Human papillomavirus (HPV) is the most common sexually transmitted infection worldwide and it is responsible for most cases of cervical uterine cancer. Although HPV infections of the cervix do not always progress to cancer, 90% of cervical cancer cases have been found to be associated with high risk HPV (HR- HPV) infection. HPV DNA testing is widely used, along with Papanicolaou (Pap) testing, to screen for cervical abnormalities. However, there are no data on the prevalence of genotype-specific HPV infections assessed by measuring HPV E6/E7 mRNA in women representative of the Chinese population across a broad age range.
  
  
  METHODS
  In the present study, we compared the results with the CervicGen HPV RT-qDx assay, which detects 16 HR-HPV genotypes (Alpha-9: HPV 16, 31, 33, 35, 52, and 58; Alpha-7: HPV 18, 39, 45, 51, 59, and 68; and Alpha-5, 6: HPV 53, 56, 66, and 69), and the REBA HPV-ID assay, which detects 32 HPV genotypes based on the reverse blot hybridization assay (REBA) for the detection of oncogenic HPV infection according to cytological diagnosis. We also investigated the prevalence and genotype distribution of HPV infection with a total of 324 liquid-based cytology samples collected in western Shandong province, East China.
  
  
  RESULTS
  The overall HPV prevalences determined by HPV DNA and HPV E6/E7 mRNA assays in this study were 79.9% (259/324) and 55.6% (180/324), respectively. Although the positivity of HPV E6/E7 mRNA expression was significantly lower than HPV DNA positivity, the HPV E6/E7 mRNA assay showed greater specificity than the HPV DNA assay (88.6% vs. 48.1%) in normal cytology samples. The prevalence of Alpha-9 (HPV 16, 31, 33, 35, 52, and 58) HPV infection among these women accounted for up to 80.3% and 76.1% of the high-grade lesions detected in the HPV mRNA and DNA tests, respectively. The HR-HPV genotype distribution, based on HPV DNA and E6/E7 mRNA expression by age group in patients with cytologically confirmed lesions, was highest in women aged 40 to 49 years (35.9% for cytologically confirmed cases, Pearson correlation r value=0.993, p<0.001) for high-grade lesions. Among the oncogenic HR-HPV genotypes for all age groups, there was little difference in the distribution of HPV genotypes between the HPV DNA (HPV -16, 53, 18, 58, and 33) and HPV E6/E7 mRNA (HPV -16, 53, 33, 58, and 18) assays. HPV 16 was the most common HPV genotype among women with high- grade lesions.
  
  
  CONCLUSIONS
  Our results suggest that the HPV E6/E7 mRNA assay can be a sensitive and specific tool for the screening and investigation of cervical cancer. Furthermore, it may provide useful information regarding the necessity for early cervical cancer screenings and the development of additional effective HPV vaccines, such as one for HPV 53 and 58. Additionally, gaining knowledge of HPV distribution may also inform us about ecological changes in HPV after the vaccination.
authors.affiliation: Wonju Eco Environmental Technology Center, Wonju, Gangwon, Republic of Korea E-mail : abba@yonsei.ac.kr, hyelee@yonsei.ac.kr.
authors.forename: Hye-young
authors.initials: HY
authors.lastname: Wang
authors.forename: Dongsup
authors.initials: D
authors.lastname: Lee
authors.forename: Sunyoung
authors.initials: S
authors.lastname: Park
authors.forename: Geehyuk
authors.initials: G
authors.lastname: Kim
authors.forename: Sunghyun
authors.initials: S
authors.lastname: Kim
authors.forename: Lin
authors.initials: L
authors.lastname: Han
authors.forename: Ren
authors.initials: R
authors.lastname: Yubo
authors.forename: Yingxue
authors.initials: Y
authors.lastname: Li
authors.forename: Kwang Hwa
authors.initials: KH
authors.lastname: Park
authors.forename: Hyeyoung
authors.initials: H
authors.lastname: Lee
mesh_terms: D000328:Adult; D000368:Aged; D052685:Alphapapillomavirus / Q000235:genetics / Q000302:isolation & purification; D002584:Cervix Uteri / Q000473:pathology / Q000821:virology*; D002681:China / Q000453:epidemiology; D004279:DNA, Viral / Q000032:analysis* / Q000235:genetics; D055088:Early Detection of Cancer; D005260:Female; D005838:Genotype; D061809:Human Papillomavirus DNA Tests / Q000379:methods*; D006801:Humans; D015151:Immunoblotting; D008875:Middle Aged; D065006:Papanicolaou Test; D050725:Papillomavirus E7 Proteins / Q000235:genetics*; D030361:Papillomavirus Infections / Q000175:diagnosis* / Q000453:epidemiology / Q000821:virology; D012333:RNA, Messenger / Q000032:analysis* / Q000235:genetics; D012367:RNA, Viral / Q000032:analysis / Q000235:genetics; D002583:Uterine Cervical Neoplasms / Q000175:diagnosis; D055815:Young Adult; D002578:Uterine Cervical Dysplasia / Q000175:diagnosis
chemical_list: D004279:DNA, Viral; D050725:Papillomavirus E7 Proteins; D012333:RNA, Messenger; D012367:RNA, Viral